A new study in JAMA Network Open found that almost all Medicaid managed care plans (MCPs) cover at least one of the four formulations of naloxone. Eighty percent of Medicaid recipients, which include more than 70 million people, are enrolled in these plans. The study is the first to assess naloxone coverage within MCPs.

Esophageal adenocarcinoma (EAC) is the sixth most deadly cancer worldwide for which no effective targeted therapy exists. Patients need to rely on chemotherapy which is started ahead of surgical interventions in the hope to shrink or control tumors. However, most patients become resistant to certain NACTs, leading to poor outcomes.

To enable clinicians to rapidly test different chemotherapies and determine the best treatment courses, Wyss Institute researchers and their collaborators at McGill University have developed a precision oncology Organ Chip platform that accurately and actionably predicts chemotherapy responses of individual patients with EAC in a clinically useful timeframe.